DUBLIN--(BUSINESS WIRE)--The "In Situ Hybridization: US Market Shares, Strategy, and Forecasts, 2018 to 2024" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.
The US market for In Situ Hybridization (ISH) at $4.3 billion in 2017 and is anticipated to reach $7.8 billion by 2024, with CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.
US markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).
Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions. Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.
In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizationsthe nucleic acid probe is synthesized, labeled, purified, and annealed with the specific targetthe difference is the greater amount of information gained by visualizing the results within the tissue.
Key Topics:
- In Situ Hybridization
- Molecular Diagnostics
- Cervical Cancer Stain
- Fish Steps Reduction
- Fluorescence In Situ
- Hybridization (FISH)
- In Situ Hybridization (ISH)
- FISH Probe Kit
- Cancer
- Chromosonal Abnormalities
- Infectious Diseases
- Inflammatory Diseases
- Fluorescence In Situ
- Hybridization (FISH)
- Chromogenic In Situ
- Hybridization (CISH)
- Human Genetic Tests
- Microbial Tests
- In Vitro Diagnostics
- System for the Analysis of Solid Tumors
- Hybridization Technique
- Detection of Long Non
- Coding DNA
-
Coding RNA
Key Topics Covered:
1. US In situ Hybridization Executive Summary
2. United States In Situ Hybridization ISH Market Definition and Market Dynamics
3. In-Situ Hybridization Market Shares and Market Forecasts
4. In-Situ Hybridization Research and Technology
5. In-Situ Hybridization Company Profiles
6. Summary and Conclusions
7. Appendix A: List Of Nucleic Acid-Based Tests
Companies Mentioned
- Abbott Laboratories
- Acupath Laboratories
- Advanced Cell Diagnostics
- Agilent Technologies
- Bio SB Zytovision Molecular Diagnostics
- Bio-Techne
- BioGenex Laboratories
- Biotechne US
- Chromogenic In Situ Hybridization (CISH)
- Danaher
- Exiqon A/S
- F. Hoffmann-La Roche AG
- Leica Biosystems Nussloch GmbH
- Merck KGaA
- PerkinElmer
- Qiagen
- Roche Immuno Diagnostics
- Thermo Fisher Scientific
- Vysis
For more information about this report visit https://www.researchandmarkets.com/research/3nzp2x/united_states?w=4
